April 24th 2024
In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
Study: PET/MRI May Prevent Up to 83 Percent of Unnecessary Biopsies in Men with PI-RADS 3 Lesions
March 15th 2024For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.
Can Autonomous AI Help Reduce Prostate MRI Workloads Without Affecting Quality?
March 1st 2024Based on findings from a multicenter study of over 1,600 patients, researchers at the European Congress of Radiology suggest the inclusion of autonomous artificial intelligence (AI) triage could facilitate up to a 75 percent reduction in prostate MRI reading workload.
ECR Study Examines Key Predictive Factors for Metastasis in Patients with High-Risk Prostate Cancer
February 28th 2024Sixty-five percent of patients with newly diagnosed high-risk prostate cancer may have extraprostatic extension on MRI, and PSMA PET/CT findings suggest those with Gleason scores of eight or higher have more than double the risk of metastasis, according to a new study presented at the European Congress of Radiology (ECR).
New Research Evaluates PI-RADS Upgrading Rules in MRI Exams for Prostate Cancer
February 15th 2024In a recent assessment of PI-RADS upgrading rules, researchers found that ignoring the upgrading rules would lead to one missed diagnosis of clinically significant prostate cancer per 5.5 biopsies avoided with MRI-focused risk pathways.
Can Combination of mpMRI and Extracellular Vesicle-Based Biomarkers Enhance csPCa Detection?
January 29th 2024A multivariable model that includes mpMRI and blood testing assessment of prostate extracellular vesicles had a significantly higher AUC and sensitivity rate than mpMRI alone for predicting clinically significant prostate cancer, according to research presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU).
What Post-Void MRIs May Reveal About Midline Radiotracer Activity on PSMA PET/CT
January 26th 2024Patients with localized high-risk prostate cancer and midline radiotracer activity in the prostate had over double the incidence of urethral hyperintensity on T2W MRI, according to research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).
Positive Target of MRI: Could It be a Key Predictive Factor in Upgrading of Prostate Cancer Risk?
January 19th 2024Researchers found that a positive target of MRI led to a threefold increased risk for Gleason Grading Group (GGG) upgrading after radical prostatectomy in patients with low prostate cancer risk.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Do Bone Scans Over Stage Prostate Cancer? What a Multicenter Study Reveals
November 16th 2023Fifty-seven percent of patients with prostate cancer diagnosed with osseous metastases on bone scans had negative findings on PSMA PET imaging, according to findings from an international multicenter comparative study.